Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focused on RNA medicines, announced that President and CEO Paul Bolno will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City.
The presentation is scheduled for Wednesday, May 20, 2026 at 8:00 a.m. ET, with a live webcast and replay accessible for a limited time via the Investors section of the company website under Investor Events.
Wave Life Sciences (Nasdaq: WVE) reported Q1 2026 results and a pipeline update. Cash and equivalents were $544.6M as of March 31, 2026, with runway into 3Q 2028. Key clinical milestones include FDA acceptance of the Phase 2a multidose INLIGHT trial for WVE-007 and upcoming AATD data presentations in May 2026.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on April 28, 2026 to review first quarter 2026 financial results and provide business updates.
Investors and analysts can access the live event via the company’s Investor Events page, participate in a live Q&A, and find an archived webcast afterward.
Wave Life Sciences (Nasdaq: WVE) has applied to redomicile its parent company from Singapore to the United States via a Scheme of Arrangement under Section 210 of the Companies Act 1967 (Singapore).
The company filed the application on April 16, 2026. A Singapore High Court hearing is set for April 29, 2026 at 10:00 am SGT. Affidavits and written submissions are due April 22 and April 24, 2026, respectively. The Scheme remains subject to shareholder and court approval, and filing materials will be posted on the company investor relations website.
Wave Life Sciences (Nasdaq: WVE) announced its board approved a plan to redomicile the parent company from Singapore to the United States, creating a new Delaware parent corporation.
The one-for-one share exchange will preserve Nasdaq listing and ticker WVE, is expected to take effect in mid-2026, is subject to shareholder and Singapore High Court approvals, and is expected to be tax-free to U.S. shareholders.
Wave Life Sciences (NASDAQ: WVE) reported positive Phase 1 INLIGHT interim data for WVE-007: a single 240 mg dose produced placebo-adjusted -14.3% visceral fat (p<0.05) and -3.3% waist circumference at six months, with lean mass +2.4% and durable Activin E suppression up to 88%. WVE-007 was generally safe to 600 mg with no serious TEAEs. Phase 2a multidose (BMI 35–50 kg/m2) is on track to start in 2Q 2026 to evaluate heavier individuals and additional cardiometabolic endpoints.
Wave Life Sciences (Nasdaq: WVE) announced acceptance of a late-breaking oral presentation of data from its RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference, May 15-20, 2026 in Orlando.
The presentation will include new data from the 400 mg multidose cohort and the 600 mg single dose cohort, and is scheduled for May 18, 2026 at 4:03 p.m. ET. The company expects regulatory feedback on a potential accelerated approval pathway for WVE-006 mid-2026 and said INLIGHT trial data for WVE-007 is expected this month.
Wave Life Sciences (Nasdaq: WVE) reported Q4 and full-year 2025 results and a business update on Feb 26, 2026. Key points: $602.1M cash (Dec 31, 2025) with runway into 3Q 2028, advancing WVE-007 INLIGHT obesity program with 240 mg and 400 mg data due 1Q 2026, RestorAATion-2 fully enrolled through 600 mg with 400 mg multidose data in 1Q 2026, WVE-008 CTA on track for 2026, and ongoing GSK collaboration milestones.
Financials: 2025 revenue $42.7M, net loss $204.4M, R&D $182.8M. Investor webcast at 8:30 a.m. ET today.
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived for a limited time.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026 to review fourth quarter and full year 2025 financial results and provide business updates.
Investors can access the event via the company’s Investor Events page; an archived webcast will be posted on the Wave Life Sciences website after the live event.